AstraZeneca PLC : A technical turn-around configuration
| Entry price | Target | Stop-loss | Potential |
|---|
|
GBX 11,266.5 |
GBX 12,500 |
GBX 10,900 |
+10.95% |
|---|
AstraZeneca PLC reflects attractive technical aspects that could allow investors to expect a trend reversal over the medium term.
Summary● According to MSCI, the company's ESG score for its industry is good.
● The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
● The group's activity appears highly profitable thanks to its outperforming net margins.
● Over the last twelve months, the sales forecast has been frequently revised upwards.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The company's enterprise value to sales, at 3.45 times its current sales, is high.
● The company appears highly valued given the size of its balance sheet.
● The group usually releases earnings worse than estimated.
© MarketScreener.com -
2025
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener UK. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
